Everything below concerns GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Nalmefene, sold under the brand name Revex among others, is a medication that is used in the treatment of opioid overdose and alcohol dependence. Nalmefene belongs to the class of opioid antagonists and can be taken by mouth, administered by injection, or delivered through nasal administration. In terms of its chemical structure and biological activity, nalmefene is similar to another opioid antagonist called naltrexone, as they are both derivatives of opiates. However, nalmefene offers certain advantages over naltrexone. These include a longer elimination half-life, which means it stays in the body for a longer duration, improved absorption when taken by mouth, and no observed liver toxicity that is dependent on the dosage. Nalmefene is available as a generic medication.
Francis Aston was born in Harborne, now part of Birmingham, on 1 September 1877. He was the third child and second son of William Aston and Fanny Charlotte Hollis. He was educated at the Harborne Vicarage School and later Malvern College in Worcestershire where he was a boarder. In 1893 Francis William Aston began his university studies at Mason College (which was then external college of University of London) where he was taught physics by John Henry Poynting and chemistry by Frankland and Tilden. From 1896 on he conducted additional research on organic chemistry in a private laboratory at his father's house. In 1898 he started as a student of Frankland financed by a Forster Scholarship; his work concerned optical properties of tartaric acid compounds. He started to work on fermentation chemistry at the school of brewing in Birmingham and was employed by W. Butler & Co. Brewery in 1900. This period of employment ended in 1903 when he returned to the University of Birmingham under Poynting as an Associate.
== Diagnosis == The diagnosis of MBS is heavily dependent on the presentation and histopathology of its tumors. Of particular importance, the presence of pseudo-lipoblasts in a myxoid sarcoma-like background is an extremely strong indicator that the tumor is a MFS. and tumors with a myxofibrosarcoma-like histopathology that initiate in the retroperitoneum, abdominal cavity, or pelvis are nearly always dedifferentiated liposarcomas. Magnetic resonance imaging (MRI) has been helpful in diagnosing MBS. On T2-weighted MRI, 81% of MFS tumors give a tail sign, i.e. a multidirectional signal spreading away from the main mass along a facial plane (i.e. a line or band of connective tissue). Among all myxoid-predominant tissue lesions, this MRI method diagnoses MBS with a specificity of 79% to 90%. This MRI finding is also extremely valuable for gauging the extent and depth of surgery needed to completely remove MBS tumors.
In March 2018 Sara Rojas and her team published their research on drug incorporation and delivery with various biocompatible MOFs other than CD-MOF-1 through simulated cutaneous administration. The group studied the loading and release of ibuprofen (hydrophobic) and aspirin (hydrophilic) in three biocompatible MOFs (MIL-100(Fe), UiO-66(Zr), and MIL-127(Fe)). Under simulated cutaneous conditions (aqueous media at 37 °C) the six different combinations of drug-loaded MOFs fulfilled "the requirements to be used as topical drug delivery systems, such as released payload between 1 and 7 days" and delivering a therapeutic concentration of the drug of choice without causing unwanted side effects. The group discovered that the drug uptake is "governed by the hydrophilic/hydrophobic balance between cargo and matrix" and "the accessibility of the drug through the framework". The "controlled release under cutaneous conditions follows different kinetics profiles depending on: (i) the structure of the framework, with either a fast delivery from the open structure MIL-100 or a slower drug release from the narrow 1D pore system of MIL-127 or (ii) the hydrophobic/hydrophilic nature of the cargo, with a fast (Aspirin) and slow (Ibuprofen) release from the UiO-66 matrix." Moreover, a simple ball milling technique is used to efficiently encapsulate the model drugs 5-fluorouracil, caffeine, para-aminobenzoic acid, and benzocaine. Both computational and experimental studies confirm the suitability of [Zn4O(dmcapz)3] to incorporate high loadings of the studied bioactive molecules.
Sources: en.wikipedia.org
An important piece information gained by ion mobility are the collision cross sections (CCS). These rotationally averaged 2D-projections of the molecule, providing an insight in the global shape. In proteomics, these can be used to gain insights in the stability of protein and multi-protein complexes via collision induced dissociation (CID) experiments. While in metabolomics and glycomics, the CCS can, when coupled to mass spectrometry (MS), be used to separate isomers of the same compound. This way, adding CCS values of glycans and their fragments to databases will increase structural identification confidence and accuracy. In addition to the empirical determination, CCS values can be computationally calculated if the 3D-structure of the molecule is known. Current CCS algorithms allow ms calculation times, making them very powerful when combined with AlphaFold and/or molecular dynamic simulations. Outside of laboratory purposes, IMS has found great usage as a detection tool for hazardous substances. More than 10,000 IMS devices are in use worldwide in airports, and the US Army has more than 50,000 IMS devices. In industrial settings, uses of IMS include checking equipment cleanliness and detecting emission contents, such as determining the amount of hydrochloric and hydrofluoric acid in a stack gas from a process. It is also applied in industrial purposes to detect harmful substances in air.
He had no difficulty urinating during the flight and the urine collection system worked well, although transferring urine to storage bags in the cramped capsule proved difficult. Cooper took several naps during the flight, lasting about an hour each. He experienced some discomfort from the pressure suit compressing his knees, which he alleviated by moving his feet slightly upward. Some time before re-entry, Cooper complied with an order to consume a dextroamphetamine tablet to ensure his alertness; he reported not feeling any sleepiness for the remainder of the flight.
==== Physiological action ==== The physiological effects of labetalol when administered acutely (intravenously) are not predictable solely by their receptor blocking effect, i.e. blocking β1-adrenergic receptors should decrease heart rate, but labetalol does not. When labetalol is given in acute situations, it decreases the peripheral vascular resistance and systemic blood pressure while having little effect on the heart rate, cardiac output and stroke volume, despite its α1-, β1- and β2-adrenergic receptor blocking mechanism. These effects are mainly seen when the person is in the upright position. Long term labetalol use also has different effects from other beta blockers. Other beta blockers, such as propranolol, persistently reduce cardiac output during exercise. The peripheral vascular resistance decreases when labetalol is first administered. Continuous labetalol use further decreases peripheral vascular resistance. However, during exercise, cardiac output remains the same due to a compensatory mechanism that increases stroke volume. Thus, labetalol is able to reduce heart rate during exercise while maintaining cardiac output by the increase in stroke volume.
== Incarceration == Initially Rose was incarcerated at HM Prison Bronzefield, Middlesex, as a Category A prisoner. She was transferred to HM Prison Low Newton in County Durham in 2008. It was reported in May 1995 that Rose and Myra Hindley—who were both incarcerated in HM Prison Durham at the time (Rose was on remand)—had formed a "friendship". Hindley denied the claims as "nonsense". Rose acknowledged that they knew each other from being on the same wing but denied further speculation that the two were "having an affair". Both of Rose's eldest biological children, and her stepdaughter, Anna Marie, initially visited her in prison on a regular basis, although by 2006 she had ceased contact with them after Mae began asking questions about her culpability in the murders. Rose justified her decision with the explanation: "I was never a parent [then] and could never be now." In 2019 Rose was transferred to HM Prison New Hall in West Yorkshire. It was reported the transfer had taken place after serial killer Joanna Dennehy, who had just been transferred to Low Newton, had threatened to kill Rose, although official sources stated that the reports were untrue.
== Further reading == Cimaz, Rolando (2016). "Systemic-onset juvenile idiopathic arthritis". Autoimmunity Reviews. 15 (9): 931–934. doi:10.1016/j.autrev.2016.07.004. PMID 27392503. Mellins, Elizabeth D.; Macaubas, Claudia; Grom, Alexei A. (2011). "Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions". Nature Reviews Rheumatology. 7 (7): 416–426. doi:10.1038/nrrheum.2011.68. ISSN 1759-4790. PMC 4180659. PMID 21647204.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.